

Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)

NCT06912633

Status	RECRUITING
Phase	Phase 2
Sponsor	jCyte, Inc
Enrollment	60 participants

Key Eligibility Criteria

Inclusion (17)

- Clinical diagnosis of RP supported by at least 2 of the following clinical findings: (1) Loss of peripheral vision on formal visual field testing, (2) Symptoms of night blindness or difficulty adjusting to dim light, or (3) Optical coherence tomography (OCT) outer retinal atrophy consistent with RP.
- Electroretinography (ERG) results that support diagnosis of RP including nondetectable or severely reduced rod responses (defined as less than 30% of the lower limit of normative values for the ERG lab performing the test), with prolonged implicit time OU (i.e., ensure bilateral involvement) and greater rod than cone loss. If genotyping results from a certified genetic testing lab document mutations clearly diagnostic of RP, with no other potential diagnosis of a disease(s) distinct from RP, the genetic test may be used in lieu of an ERG.
- Subject age e 18 years and d 60 years at time of signing of consent.
- Interocular BCVA disparity d 15 letters.
- Central subfield thickness (CST) e 130 µm in the study eye.

... and 12 more (see full listing online)

Exclusion (17)

- Participation in any clinical trial of a drug intervention within the last 6 months, with the exception of a N-acetyl cysteine (NAC) study.
- History of ocular treatment with any non-approved, experimental, investigational or neuroprotectant therapy (systemic, topical, intravitreal) or device in either eye, including previous jCyte clinical trials. Individuals with a history of NAC treatment may take part in the study following a 7-day washout period (prior to Baseline testing).
- Subject is currently breast feeding/pumping or is planning to breast feed/pump during the 12 months after study treatment.
- Subject is pregnant or intends to become pregnant less than 12 months after jCell injection.
- Known allergy to gentamicin.

... and 12 more (see full listing online)

Locations (14 total)

Associated Retina Consultants, Phoenix, Arizona, United States
California Retina Consultants, Bakersfield, California, United States
Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
... and 11 more locations

<https://clinicaltrials.gov/study/NCT06912633>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.